Wegovy Pill vs Foundayo: Oral GLP-1s Compared

The arrival of Foundayo — Eli Lilly's orforglipron, FDA-approved for weight management in April 2026 — means patients finally have two oral GLP-1 options to weigh. Both are once-daily pills for chronic weight management. Underneath, they're built differently: Wegovy pills contain semaglutide, a peptide GLP-1; Foundayo contains orforglipron, a small-molecule, non-peptide GLP-1 agonist.

The convenience trade-off

Foundayo's signature feature is flexibility: it can be taken any time of day, with or without food, and without water restrictions. Wegovy pills follow the classic oral-semaglutide routine — empty stomach, small amount of water, wait before eating (see our dosage guide). If the morning routine is a dealbreaker for you, Foundayo scores a real point; most patients, though, report the routine becomes automatic within a couple of weeks.

Results: the numbers favor semaglutide

In Foundayo's 72-week pivotal trial, average weight loss ranged from about 7.4% to 11.1% depending on dose (roughly 17–25 lb), with higher-dose data reaching around 12.4%. Wegovy's oral semaglutide averaged 14% (~33 lb) over 64 weeks, with 1 in 4 participants losing 20% or more. On published averages, the semaglutide tablet currently leads — flexibility is Foundayo's edge, magnitude is Wegovy's.

Side effects

Both share the GLP-1 class profile — nausea, constipation, diarrhea, vomiting, and stomach discomfort most commonly, generally easing with gradual titration. Foundayo's label also lists effects like heartburn, belching, and hair loss among common reactions. As with any GLP-1, a doctor screens your history for contraindications first; our side effects guide covers what to expect with semaglutide.

Availability and price

Foundayo launched with manufacturer cash-pay pricing that starts around $149/month at low doses but climbs steeply — commonly cited near $299/month at the higher doses that produced its best results. Wegovy pills through our platform are $149/month for the 1.5 mg starter dose, self-pay, free to book, and charged only after a doctor approves your prescription.

Which pill should you pick?

Competition is good news either way. If any-time-of-day dosing outweighs everything else for you, Foundayo deserves a look with your doctor. If you want the oral GLP-1 with the stronger published averages at a flat starter price, Wegovy pills remain the benchmark. Book a free online consultation — a licensed doctor will match the right option to your history, with prescriptions issued in 10–15 minutes when approved.

Availability in 2026

Foundayo launched through the manufacturer's direct channel in April 2026 with retail and telehealth distribution expanding afterward — a rollout still finding its footing in many areas, with higher doses and pricing tiers phasing in over time. Wegovy pills, meanwhile, are established: our platform prescribes across all 50 states, ships approved orders the same day, and has titration pathways your doctor already knows well. For patients starting treatment now, maturity of access is a real factor — new launches are exciting, but refill reliability is what a year of treatment actually runs on.

Who tends to pick which

A pattern is emerging in early clinical conversations. Patients who prioritize maximum published results at a flat entry price lean toward the semaglutide tablet; patients for whom the empty-stomach morning routine is genuinely unworkable — rotating night shifts, medication schedules that conflict — value Foundayo's take-anytime flexibility enough to trade some average efficacy. Both are defensible choices, which is exactly why the decision belongs in a consultation rather than a comment section. Book a free visit and let a licensed doctor apply the comparison to your actual life.